Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment ...

Kuntz, MD, was a fellow about 45 years ago, there were few more devastating diagnoses than Duchenne muscular dystrophy (DMD).

Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is ...

A new Netflix documentary has fans grabbing the tissues with its sad but heartfelt story. The streaming platform has several ...

Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks ...

The global Duchenne muscular dystrophy (DMD) therapeutics market is set to grow by $4.4 billion from 2024 to 2028, with a ...

GRAND RAPIDS, Mich. (WOOD) — People hit the road for a short race Saturday to support research into Duchenne muscular ...

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.